为解决 HDACi 疗法耐药问题，湖州师范学院第一附属医院等单位研究人员开展巨噬细胞浸润及 CD47 对 HDACi 疗法影响的研究。结果发现可靶向巨噬细胞或阻断 CD47 逆转耐药。推荐阅读，助你了解癌症治疗新方向。 在癌症的世界里，一场没有硝烟的战争正在激烈上演。

在前几年，“别吃我”信号通路CD47-SIRPα，可谓是最热门的开发领域之一。 随着诸多管线的临床推进安全性问题频发，吉利德、天境医药等先锋企业 ...

In reality, however, only apoptotic cells are engulfed, apparently because their surface ligand CD47 is prevented from activating the inhibitory phagocyte receptor SIRPα. Figure 2: Formation of a ...

为探究肥胖中脂肪组织外泌体（AT-Exos）的变化及作用，研究人员发现阻断 SIRP α-CD47 轴可改善代谢，意义重大。 在人体这个复杂的 “小宇宙” 里，脂肪组织可不是只负责 “储存脂肪” 这么简单，它在全身新陈代谢和维持身体内环境稳定方面，都扮演着至关 ...

Other studies of the CD47-directed antibody in large B cell lymphoma, multiple myeloma and solid tumours are not affected as they don't include azacitidine as a study drug. "While no clear trend ...

Using a yeast-based screening, they tested around 2,600 human proteins to see which ones bound to Nest1. Only one of the proteins stuck: CD47, an immune checkpoint molecule. When the researchers ...

Blocking CD47 or its ligand, thrombospondin-1, could offer a novel strategy for enhancing bacterial clearance and improving ...

Gilead is dealing with more turbulence in its development of CD47-targeting antibody magrolimab, with a partial clinical hold placed on the drug by the FDA in acute myeloid leukaemia (AML).

In the blocking assay, CD47 antibodies successfully blocked the binding of CD47 to its ligand signal regulatory protein α (SIRPα). In the BLI affinity assay, the affinity levels of these ...